DOCSLIB.ORG

New Deletion in Low-Grade Oligodendroglioma at the Glioblastoma Suppressor Locus on Chromosome 10Q25-26

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Deletion in Low-Grade Oligodendroglioma at the Glioblastoma Suppressor Locus on Chromosome 10Q25-26 Oncogene (1997) 15, 997 ± 1000 1997 Stockton Press All rights reserved 0950 ± 9232/97 $12.00 SHORT REPORT New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26 Daniel Maier1, Domenico Comparone1, Elisabeth Taylor1, Zuwen Zhang1, Otmar Gratzl1, Erwin G Van Meir2, Rodney J Scott1 and Adrian Merlo1 1Molecular Neuro-Oncology, Departments of Research and Neurosurgery, University Hospital, Schanzenstr.46, CH-4031 Basel; 2Laboratory of Tumor Biology and Genetics, CHUV, Department of Neurosurgery, University Hospital, CH-1011 Lausanne, Switzerland Loss of heterozygosity on chromosome 10 is considered CDKN2 on 9p21 (Kamb et al., 1994; Nobori et al., to be associated with the progression of glioblastomas. 1994), have been shown to be genetically altered in Two closely related regions have recently been proposed glial neoplasms. Cytogenetic (Bigner et al., 1990; to contain the glioblastoma suppressor locus on chromo- Ransom et al., 1992) and molecular evidence some 10q25-26; a 1 cM region between the polymorphic (James et al., 1988; Rasheed et al., 1992; Karlbom et (CA)n-repeat markers D10S587 and D10S216, and an al., 1993; Fults and Pedone, 1993) suggests that area of 5 cM between the markers D10S221 and deletions on chromosome 10 are among the most D10S209. To con®rm and further delineate this region, frequent genetic alterations in glioblastomas. At least we analyzed 51 glioblastomas and 11 intermediate and three separate partial deletions have been described ± low-grade gliomas for loss of heterozygosity on chromo- most consistently loss on chromosome 10q24-26 some 10. 47/62 mostly malignant gliomas displayed (Rasheed et al., 1992; Fults and Pedone, 1993) ± complete loss of chromosome 10 and nine tumors were however, the potential tumor suppressor involved in unaltered, whereas four glioblastomas and two low-grade glioblastoma tumorigenesis has not yet been de®ned. oligodendrogliomas had partial loss on distal 10q. With Functional evidence, based on microcell-mediated these six tumors, we constructed a deletion map with transfer of major portions of chromosome 10 that increased marker density at 10q25-26 which shows two caused regression of the neoplastic phenotype, lends centromeric breakpoints at the markers D10S587 and further support to the presence of a glioblastoma D10S216, thus only con®rming the distal, but not the suppressor gene on 10q24-26 (Steck et al., 1995). It is proximal candidate glioblastoma suppressor locus. Two not known whether this putative suppressor is further out of four low-grade oligodendrogliomas displayed implicated in the development of other glial neoplasms partial deletions on 10q25-26. This suggests that deletion of oligodendrocytic or ependymal origin. on chromosome 10 is not merely a late event in the Recently, two closely related, but distinct regions on progression of glioblastomas, but could play a role chromosome 10q25-26 have been implicated to harbor earlier in the development of gliomas. the glioblastoma suppressor gene (Albarosa et al., 1996; Rasheed et al., 1995). By high density mapping, Keywords: oligodendroglioma; glioblastoma suppressor we de®ned two centromeric breakpoints in a glioblas- gene; deletion mapping; chromosome 10q25-26 toma and in a low-grade oligodendroglioma. Both point to the same 1 cM region which has been proposed to harbor the glioblastoma suppressor gene (Rasheed et al., 1995). Glial neoplasms of the central nervous system (CNS) Gliomas of dierent histopathological subtypes were account for the vast majority of primary brain tumors directly obtained from surgery and classi®ed by two and include astrocytoma, ependymoma, oligodendro- experienced neuropathologists according to the World glioma, glioblastoma, and tumors of mixed cellular Health Organisation (WHO) as summarised in Table 1. composition (Kleihues et al., 1993). Glioblastoma Using polymerase chain reaction (PCR) and the multiforme, the most common solid tumor of the conditions previously described (Merlo et al., 1994), adult CNS, represents the undierentiated end stage of DNA from glial tumor specimens and lymphocytes was glioma tumorigenesis, having a dismal prognosis with a analysed for loss of LOH by ampli®cation of 2 year survival of less than 5% (Walker et al., 1980). dinucleotide and tetranucleotide repeat-containing There is great hope that the discovery of genes sequences. We used 25 polymorphic (CA)n-dinucleo- involved in tumorigenesis will give rise to novel tide repeat markers and two polymorphic (GATA)n therapeutic strategies for solid tumors. Studies of tetranucleotide repeat markers (D10S675 and allelic loss in human tumors have provided a useful D10S676), as shown in Figure 1. Primers for these tool for localising and cloning tumor suppressor genes microsatellite markers were obtained from Research (Cavenee et al., 1985; Friend et al., 1986). Speci®c Genetics (Huntsville, AL). For microsatellite analysis, genes, such as EGFR on chromosome 7p (Libermann the forward primer was labeled with T4-polynucleotide et al., 1985), p53 on 17p (Nigro et al., 1989), p16INK4a/ kinase (New England Biolabs) and [g-32P]ATP. PCR- ampli®ed products were separated using 7% polyacry- lamide-formamide gel electrophoresis in denaturing Correspondence: A Merlo Received 6 February 1997; revised 10 April 1997; accepted 5.6 M urea followed by autoradiography at 7808C 18 April 1997 overnight. For informative cases, allelic loss was scored LOH on 10q25 ± 26 in gliomas DMaieret al 998 Table 1 Partial and complete LOH on chromosome 10 in gliomas if the radiographic signal of one allele was at least 50% Complete Partial No less in tumor DNA as compared to the corresponding Histologya LOH LOH LOH normal allele. Glioblastoma multiforme IV 45 4 2 Initially, we analysed 51 glioblastomas, two anaplas- (n=51) tic astrocytomas, three low-grade astrocytomas, two Anaplastic astrocytoma III (n=2) 2 anaplastic mixed oligoastrocytomas and four low-grade Astrocytoma II (n=3) 3 oligodendrogliomas for loss of heterozygosity on Oligoastrocytoma III (n=2) 2 Oligodendroglioma II (n=4) 2 2 chromosome 10, using 17 polymorphic microsatellite markers. Complete loss of these 17 markers was found Total (n=62) 47 (75.8%) 6 (9,7%) 9 (14.5%) in 45/51 glioblastomas (88%) and in 2/2 anaplastic aAccording to the WHO classi®cation, grades are denoted in Roman mixed oligoastrocytomas (100%) which were therefore ®gures excluded from further analysis. From the remaining 15 gliomas, nine tumors (2/51 glioblastomas, 2/2 anaplas- Figure 1 Deletion map displays partial LOH on chromosome 10q25-26 in six gliomas (four glioblastomas, GBM11, GBM991, GBM6, GBM946; two oligodendrogliomas WHO grade II, OG50, OG40). The map position of the 27 microsatellite marker used is listed according to the integrated map of chromosome 10 on the left (Moschonas, 1996). The bracketed areas denote two published candidate regions on 10q25 (Albarosa et al., 1996; Rasheed et al., 1995); our own minimal area of loss is shown below between markers D10214 and D10S212. Black rectangles, LOH; white rectangles, retention of both informative alleles; SH, shift (allelic expansion or deletion); NI, not informative LOH on 10q25 ± 26 in gliomas DMaieret al 999 tic astrocytomas WHO grade III, 3/3 astrocytomas GBM 946 OG 40 WHO grade II and 2/4 oligodendrogliomas WHO N T N T grade II) did not display any loss on chromosome 10, whereas four glioblastomas and two low-grade oligodendrogliomas had partial LOH on 10q. The distribution of complete and partial losses on chromosome 10 is shown in Table 1. With regard to overall genetic alterations, 49/51 glioblastomas (96%), 2/2 mixed anaplastic oligoastrocytomas (100%) and 2/4 low-grade oligodendrogliomas (50%) displayed either partial or complete loss on chromosome 10. Our initial mapping data, based on four glioblasto- D10S209 D10S209 mas and two low-grade oligodendrogliomas with partial LOH pointed to a large region of approxi- mately 23 cM on 10q25-26 potentially harboring a glioma suppressor locus. To increase mapping resolu- tion, we used 10 additional polymorphic dinucleotide (CA)n-repeat markers from this area (Gyapay et al., D10S587 D10S587 1994). The results obtained from these six tumors are summarized in Figure 1. Mapping data and autoradio- graphs, as shown in Figure 2, demonstrate the centromeric breakpoints in the two most informative gliomas, a glioblastoma (GBM 946) and a low-grade oligodendroglioma (OG40). These two tumors con®rm one of the two closely related regions with a 1 cM area bounded by the markers D10S587 and D10S216 which D10S216 D10S216 has previously been suspected to harbor a glioblastoma suppressor gene (Rasheed et al., 1995). However, it would exclude the other candidate region between the markers D10S221 and D10S209 (Albarosa et al., 1996) that lies more towards the centromere. Taking together our mapping data and the data published (Rasheed et al., 1995), the putative suppressor gene would lie adjacent to the dinucleotide marker D10S216. More- over, the recombination event in glioblastoma GBM946, as shown in Figure 2, might lend further support to this notion. In this tumor, the very distal markers on 10q25-26 display nearly complete allelic D10S169 D10S575 loss while the marker D10S216 at the breakpoint only shows a partial loss of the larger allele whereas more proximal markers clearly retain both copies of chromosome 10. This partial loss of one allele of the marker D10S216 could be accounted for by the presence of a subpopulation of cells within the tumor that
Load more

Recommended publications
  • Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart
    Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Use this chart to code histology. The tree is arranged Chart Instructions: Neuroepithelial in descending order. Each branch is a histology group, starting at the top (9503) with the least specific terms and descending into more specific terms. Ependymal Embryonal Pineal Choro id plexus Neuronal and mixed Neuroblastic Glial Oligodendroglial tumors tumors tumors tumors neuronal-glial tumors tumors tumors tumors Pineoblastoma Ependymoma, Choroid plexus Olfactory neuroblastoma Oligodendroglioma NOS (9391) (9362) carcinoma Ganglioglioma, anaplastic (9522) NOS (9450) Oligodendroglioma (9390) (9505 Olfactory neurocytoma Ganglioglioma, malignant (()9521) anaplastic (()9451) Anasplastic ependymoma (9505) Olfactory neuroepithlioma Oligodendroblastoma (9392) (9523) (9460) Papillary ependymoma (9393) Glioma, NOS (9380) Supratentorial primitive Atypical EdEpendymo bltblastoma MdllMedulloep ithliithelioma Medulloblastoma neuroectodermal tumor tetratoid/rhabdoid (9392) (9501) (9470) (PNET) (9473) tumor
    [Show full text]
  • Paraganglioma (PGL) Tumors in Patients with Succinate Dehydrogenase-Related PCC–PGL Syndromes: a Clinicopathological and Molecular Analysis
    T G Papathomas and others Non-PCC/PGL tumors in the SDH 170:1 1–12 Clinical Study deficiency Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC–PGL syndromes: a clinicopathological and molecular analysis Thomas G Papathomas1, Jose Gaal1, Eleonora P M Corssmit2, Lindsey Oudijk1, Esther Korpershoek1, Ketil Heimdal3, Jean-Pierre Bayley4, Hans Morreau5, Marieke van Dooren6, Konstantinos Papaspyrou7, Thomas Schreiner8, Torsten Hansen9, Per Arne Andresen10, David F Restuccia1, Ingrid van Kessel6, Geert J L H van Leenders1, Johan M Kros1, Leendert H J Looijenga1, Leo J Hofland11, Wolf Mann7, Francien H van Nederveen12, Ozgur Mete13,14, Sylvia L Asa13,14, Ronald R de Krijger1,15 and Winand N M Dinjens1 1Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands, 2Department of Endocrinology, Leiden University Medical Center, Leiden,The Netherlands, 3Section for Clinical Genetics, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway, 4Department of Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands, 5Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands, 6Department of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, 7Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany, 8Section for Specialized Endocrinology,
    [Show full text]
  • Central Nervous System Tumors General ~1% of Tumors in Adults, but ~25% of Malignancies in Children (Only 2Nd to Leukemia)
    Last updated: 3/4/2021 Prepared by Kurt Schaberg Central Nervous System Tumors General ~1% of tumors in adults, but ~25% of malignancies in children (only 2nd to leukemia). Significant increase in incidence in primary brain tumors in elderly. Metastases to the brain far outnumber primary CNS tumors→ multiple cerebral tumors. One can develop a very good DDX by just location, age, and imaging. Differential Diagnosis by clinical information: Location Pediatric/Young Adult Older Adult Cerebral/ Ganglioglioma, DNET, PXA, Glioblastoma Multiforme (GBM) Supratentorial Ependymoma, AT/RT Infiltrating Astrocytoma (grades II-III), CNS Embryonal Neoplasms Oligodendroglioma, Metastases, Lymphoma, Infection Cerebellar/ PA, Medulloblastoma, Ependymoma, Metastases, Hemangioblastoma, Infratentorial/ Choroid plexus papilloma, AT/RT Choroid plexus papilloma, Subependymoma Fourth ventricle Brainstem PA, DMG Astrocytoma, Glioblastoma, DMG, Metastases Spinal cord Ependymoma, PA, DMG, MPE, Drop Ependymoma, Astrocytoma, DMG, MPE (filum), (intramedullary) metastases Paraganglioma (filum), Spinal cord Meningioma, Schwannoma, Schwannoma, Meningioma, (extramedullary) Metastases, Melanocytoma/melanoma Melanocytoma/melanoma, MPNST Spinal cord Bone tumor, Meningioma, Abscess, Herniated disk, Lymphoma, Abscess, (extradural) Vascular malformation, Metastases, Extra-axial/Dural/ Leukemia/lymphoma, Ewing Sarcoma, Meningioma, SFT, Metastases, Lymphoma, Leptomeningeal Rhabdomyosarcoma, Disseminated medulloblastoma, DLGNT, Sellar/infundibular Pituitary adenoma, Pituitary adenoma,
    [Show full text]
  • Central Neurocytoma SNP Array Analyses, Subtel FISH, and Review
    Pathology - Research and Practice 215 (2019) 152397 Contents lists available at ScienceDirect Pathology - Research and Practice journal homepage: www.elsevier.com/locate/prp Case report Central neurocytoma: SNP array analyses, subtel FISH, and review of the T literature Caroline Sandera,1, Marco Wallenborna,b,1, Vivian Pascal Brandtb, Peter Ahnertc, Vera Reuscheld, ⁎ Christan Eisenlöffele, Wolfgang Kruppa, Jürgen Meixensbergera, Heidrun Hollandb, a Dept. of Neurosurgery, University of Leipzig, Liebigstraße 26, 04103 Leipzig, Germany b Saxonian Incubator for Clinical Translation, University of Leipzig, Philipp-Rosenthal Str. 55, 04103 Leipzig, Germany c Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstraße 16-18, 04107 Leipzig, Germany d Dept. of Neuroradiology, University of Leipzig, Liebigstraße 22a, 04103 Leipzig, Germany e Dept. of Neuropathology, University of Leipzig, Liebigstraße 26, 04103 Leipzig, Germany ARTICLE INFO ABSTRACT Keywords: The central neurocytoma (CN) is a rare brain tumor with a frequency of 0.1-0.5% of all brain tumors. According Central neurocytoma to the World Health Organization classification, it is a benign grade II tumor with good prognosis. However, Cytogenetics some CN occur as histologically “atypical” variant, combined with increasing proliferation and poor clinical SNP array outcome. Detailed genetic knowledge could be helpful to characterize a potential atypical behavior in CN. Only FISH few publications on genetics of CN exist in the literature. Therefore, we performed cytogenetic analysis of an intraventricular neurocytoma WHO grade II in a 39-year-old male patient by use of genome-wide high-density single nucleotide polymorphism array (SNP array) and subtelomere FISH. Applying these techniques, we could detect known chromosomal aberrations and identified six not previously described chromosomal aberrations, gains of 1p36.33-p36.31, 2q37.1-q37.3, 6q27, 12p13.33-p13.31, 20q13.31-q13.33, and loss of 19p13.3-p12.
    [Show full text]
  • Inhibition of Mir-1193 Leads to Synthetic Lethality in Glioblastoma
    Zhang et al. Cell Death and Disease (2020) 11:602 https://doi.org/10.1038/s41419-020-02812-3 Cell Death & Disease ARTICLE Open Access Inhibition of miR-1193 leads to synthetic lethality in glioblastoma multiforme cells deficient of DNA-PKcs Jing Zhang1,LiJing1,SubeeTan2, Er-Ming Zeng3, Yingbo Lin4, Lingfeng He 1, Zhigang Hu 1, Jianping Liu1 and Zhigang Guo1 Abstract Glioblastoma multiforme (GBM) is the most malignant primary brain tumor and has the highest mortality rate among cancers and high resistance to radiation and cytotoxic chemotherapy. Although some targeted therapies can partially inhibit oncogenic mutation-driven proliferation of GBM cells, therapies harnessing synthetic lethality are ‘coincidental’ treatments with high effectiveness in cancers with gene mutations, such as GBM, which frequently exhibits DNA-PKcs mutation. By implementing a highly efficient high-throughput screening (HTS) platform using an in-house-constructed genome-wide human microRNA inhibitor library, we demonstrated that miR-1193 inhibition sensitized GBM tumor cells with DNA-PKcs deficiency. Furthermore, we found that miR-1193 directly targets YY1AP1, leading to subsequent inhibition of FEN1, an important factor in DNA damage repair. Inhibition of miR-1193 resulted in accumulation of DNA double-strand breaks and thus increased genomic instability. RPA-coated ssDNA structures enhanced ATR checkpoint kinase activity, subsequently activating the CHK1/p53/apoptosis axis. These data provide a preclinical theory for the application of miR-1193 inhibition as a potential synthetic lethal approach targeting GBM cancer cells with DNA-PKcs fi 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; de ciency. Introduction In response to DNA damage, cells activate the DNA Glioblastoma multiforme (GBM), exhibits highly damage response (DDR) network, allowing DNA repair aggressive invasion, a high mortality rate, and high resis- through the regulation of cell-cycle progression, DNA tance to radiation and cytotoxic chemotherapy, and thus damage repair or apoptosis4.
    [Show full text]
  • A Case of Mushroom‑Shaped Anaplastic Oligodendroglioma Resembling Meningioma and Arteriovenous Malformation: Inadequacies of Diagnostic Imaging
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 10: 1499-1502, 2015 A case of mushroom‑shaped anaplastic oligodendroglioma resembling meningioma and arteriovenous malformation: Inadequacies of diagnostic imaging YAOLING LIU1,2, KANG YANG1, XU SUN1, XINYU LI1, MINGHAI WEI1, XIANG'EN SHI2, NINGWEI CHE1 and JIAN YIN1 1Department of Neurosurgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116044; 2Department of Neurosurgery, Affiliated Fuxing Hospital, The Capital University of Medical Sciences, Beijing 100038, P.R. China Received December 29, 2014; Accepted June 29, 2015 DOI: 10.3892/etm.2015.2676 Abstract. Magnetic resonance imaging (MRI) is the most tomas (WHO IV) (2). The median survival times of patients widely discussed and clinically employed method for the with WHO II and WHO III oligodendrogliomas are 9.8 and differential diagnosis of oligodendrogliomas; however, 3.9 years, respectively (1,2), and 6.3 and 2.8 years, respec- MRI occasionally produces unclear results that can hinder tively, if mixed with astrocytes (3,4). Surgical excision and a definitive oligodendroglioma diagnosis. The present study postoperative adjuvant radiotherapy is the traditional therapy describes the case of a 34-year-old man that suffered from for oligodendroglioma; however, studies have observed that, headache and right upper‑extremity weakness for 2 months. among intracranial tumors, anaplastic oligodendrogliomas Based on the presurgical evaluation, it was suggested that the are particularly sensitive to chemotherapy, and the prognosis patient had a World Health Organization (WHO) grade II-II of patients treated with chemotherapy is more favorable glioma, meningioma or arteriovenous malformation (AVM), than that of patients treated with radiotherapy (5‑7).
    [Show full text]
  • The New WHO Classification of Brain Tumors and Molecular Profiling in the Diagnosis of Gliomas
    The New WHO Classification of Brain Tumors and Molecular Profiling in the Diagnosis of Gliomas Aivi Nguyen, MD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial neoplasms – infiltrating gliomas Astrocytic tumors • Diffuse astrocytoma II • Anaplastic astrocytoma III • Glioblastoma • Giant cell glioblastoma IV • Gliosarcoma Oligodendroglial tumors • Oligodendroglioma II • Anaplastic oligodendroglioma III Oligoastrocytic tumors • Oligoastrocytoma II • Anaplastic oligoastrocytoma III Courtesy of Dr. Maria Martinez-Lage 2 2016 3 The 2016 WHO classification of tumours of the central nervous system Louis et al., Acta Neuropathologica 2016 4 Talk Outline Genetic, epigenetic and metabolic changes in gliomas • Mechanisms/tumor biology • Incorporation into daily practice and WHO classification Penn’s Center for Personalized Diagnostics • Tests performed • Results and observations to date Summary 5 The 2016 WHO classification of tumours of the central nervous system Louis et al., Acta Neuropathologica 2016 6 Mechanism of concurrent 1p and 19q chromosome loss in oligodendroglioma lost FUBP1 CIC Whole-arm translocation Griffin et al., Journal of Neuropathology and Experimental Neurology 2006 7 Oligodendroglioma: 1p19q co-deletion Since the 1990s Diagnostic Prognostic Predictive Li et al., Int J Clin Exp Pathol 2014 8 Mutations of Selected Genes in Glioma Subtypes GBM Astrocytoma Oligodendroglioma Oligoastrocytoma Killela et al., PNAS 2013 9 Escaping Senescence Telomerase reverse transcriptase gene
    [Show full text]
  • Epidemiology and Survival of Patients with Brainstem Gliomas: a Population-Based Study Using the SEER Database
    ORIGINAL RESEARCH published: 11 June 2021 doi: 10.3389/fonc.2021.692097 Epidemiology and Survival of Patients With Brainstem Gliomas: A Population-Based Study Using the SEER Database † † Huanbing Liu 1 , Xiaowei Qin 1 , Liyan Zhao 2, Gang Zhao 1* and Yubo Wang 1* 1 Department of Neurosurgery, First Hospital of Jilin University, Changchun, China, 2 Department of Clinical Laboratory, Second Hospital of Jilin University, Changchun, China Background: Brainstem glioma is a primary glial tumor that arises from the midbrain, Edited by: pons, and medulla. The objective of this study was to determine the population-based Yaohua Liu, epidemiology, incidence, and outcomes of brainstem gliomas. Shanghai First People’s Hospital, China Methods: The data pertaining to patients with brainstem gliomas diagnosed between Reviewed by: 2004 and 2016 were extracted from the SEER database. Descriptive analyses were Kristin Schroeder, conducted to evaluate the distribution and tumor-related characteristics of patients with Duke Cancer Institute, United States Gerardo Caruso, brainstem gliomas. The possible prognostic indicators were analyzed by Kaplan-Meier University Hospital of Policlinico G. curves and a Cox proportional hazards model. Martino, Italy *Correspondence: Results: The age-adjusted incidence rate was 0.311 cases per 100,000 person-years Gang Zhao between 2004 and 2016. A total of 3387 cases of brainstem gliomas were included in our [email protected] study. Most of the patients were white and diagnosed at 5-9 years of age. The most Yubo Wang [email protected] common diagnosis confirmed by histological review was ependymoma/anaplastic †These authors have contributed ependymoma. The median survival time was 24 months.
    [Show full text]
  • Malignant CNS Solid Tumor Rules
    Malignant CNS and Peripheral Nerves Equivalent Terms and Definitions C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753 (Excludes lymphoma and leukemia M9590 – M9992 and Kaposi sarcoma M9140) Introduction Note 1: This section includes the following primary sites: Peripheral nerves C470-C479; cerebral meninges C700; spinal meninges C701; meninges NOS C709; brain C710-C719; spinal cord C720; cauda equina C721; olfactory nerve C722; optic nerve C723; acoustic nerve C724; cranial nerve NOS C725; overlapping lesion of brain and central nervous system C728; nervous system NOS C729; pituitary gland C751; craniopharyngeal duct C752; pineal gland C753. Note 2: Non-malignant intracranial and CNS tumors have a separate set of rules. Note 3: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on date of diagnosis. • Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules • Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules • The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules. Note 4: There must be a histologic, cytologic, radiographic, or clinical diagnosis of a malignant neoplasm /3. Note 5: Tumors from a number of primary sites metastasize to the brain. Do not use these rules for tumors described as metastases; report metastatic tumors using the rules for that primary site. Note 6: Pilocytic astrocytoma/juvenile pilocytic astrocytoma is reportable in North America as a malignant neoplasm 9421/3. • See the Non-malignant CNS Rules when the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma.
    [Show full text]
  • Meningioma ACKNOWLEDGEMENTS
    AMERICAN BRAIN TUMOR ASSOCIATION Meningioma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Meningioma Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit advocacy organization dedicated solely to brain tumor research. For nearly 45 years, the ABTA has been providing comprehensive resources that support the complex needs of brain tumor patients and caregivers, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnosis, treatment and care. To learn more about the ABTA, visit www.abta.org. We gratefully acknowledge Santosh Kesari, MD, PhD, FANA, FAAN chair of department of translational neuro- oncology and neurotherapeutics, and Marlon Saria, MSN, RN, AOCNS®, FAAN clinical nurse specialist, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA; and Albert Lai, MD, PhD, assistant clinical professor, Adult Brain Tumors, UCLA Neuro-Oncology Program, for their review of this edition of this publication. This publication is not intended as a substitute for professional medical advice and does not provide advice on treatments or conditions for individual patients. All health and treatment decisions must be made in consultation with your physician(s), utilizing your specific medical information. Inclusion in this publication is not a recommendation of any product, treatment, physician or hospital. COPYRIGHT © 2017 ABTA REPRODUCTION WITHOUT PRIOR WRITTEN PERMISSION IS PROHIBITED AMERICAN BRAIN TUMOR ASSOCIATION Meningioma INTRODUCTION Although meningiomas are considered a type of primary brain tumor, they do not grow from brain tissue itself, but instead arise from the meninges, three thin layers of tissue covering the brain and spinal cord.
    [Show full text]
  • The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy
    International Journal of Molecular Sciences Review The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy Fiona A. Desland and Adília Hormigo * Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, Department of Neurology, Box 1137, 1 Gustave L. Levy Pl, New York, NY 10029-6574, USA; fi[email protected] * Correspondence: [email protected] Received: 28 August 2020; Accepted: 29 September 2020; Published: 5 October 2020 Abstract: Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumor in adults. Its aggressive nature is attributed partly to its deeply invasive margins, its molecular and cellular heterogeneity, and uniquely tolerant site of origin—the brain. The immunosuppressive central nervous system (CNS) and GBM microenvironments are significant obstacles to generating an effective and long-lasting anti-tumoral response, as evidenced by this tumor’s reduced rate of treatment response and high probability of recurrence. Immunotherapy has revolutionized patients’ outcomes across many cancers and may open new avenues for patients with GBM. There is now a range of immunotherapeutic strategies being tested in patients with GBM that target both the innate and adaptive immune compartment. These strategies include antibodies that re-educate tumor macrophages, vaccines that introduce tumor-specific dendritic cells, checkpoint molecule inhibition, engineered T cells, and proteins that help T cells engage directly with tumor cells. Despite this, there is still much ground to be gained in improving the response rates of the various immunotherapies currently being trialed. Through historical and contemporary studies, we examine the fundamentals of CNS immunity that shape how to approach immune modulation in GBM, including the now revamped concept of CNS privilege.
    [Show full text]
  • Primary Spinal Cord Oligodendroglioma: a Case Report and Review of the Literature Thara Tunthanathip* and Thakul Oearsakul
    Tunthanathip and Oearsakul Chinese Neurosurgical Journal (2016) 2:2 DOI 10.1186/s41016-015-0021-4 CASE REPORT Open Access Primary spinal cord oligodendroglioma: a case report and review of the literature Thara Tunthanathip* and Thakul Oearsakul Abstract Background: Primary spinal cord oligodendroglioma is extremely rare. In an extensive review of this disease, 53 cases were reported. Furthermore, the authors summarize the characteristics of the primary spinal cord oligodendroglioma; chronological presentation , neurological imaging, treatment and the outcome obtained in the present case as well as review the literature. Case Presentation: A 46-year-old male who had progressive neck pain for a year. Magnetic resonance imaging showed an intramedullary mass from level C2 to T4. A radical resection was performed. Histology revealed oligodendroglioma. Thereafter, the patient was treated with adjuvant radiotherapy. A year later, tumor developed recurrence. The patinet died in 3 years and 6 months. Conclusions: The available data of this disease was limited. Base on 11 published papers and the present case, surgical resection is the treatment of choice although recurrence of the tumor tends to occur after partial resection with or without radiotherapy. From the literature, the management of the recurrent disease is still surgery. Moreover, Temozolomide may be an advantage in recurrent situations. Keywords: Oligodendroglioma, Spinal cord tumor, Intramedullary tumor, Treatment Background Pinpricked sensation was suspended deficits at C5-T1 Oligodendroglioma originates from oligodendrocyte, levels. Biceps, triceps and brachioradialis, knee and which is found in either the brain or spinal cord [1]. Achilles reflexes were 2+. Further, Hoffman reflexes This tumor is commonly found in the cerebral hemi- were absent.
    [Show full text]